Renal failure is a common complication of multiple myeloma, often due to overproduction of light chains.
Case presentation:
Light chain cast nephropathy in newly-diagnosed multiple myeloma is associated with inferior outcomes. Proteasome inhibitors and immunomodulatory drugs with therapeutic plasma exchange can rapidly reduce light chain levels and confer remission; however, optimal delivery of these agents is limited by decreased renal function, and plasma exchange is often limited to tertiary centers.
Conclusion:
These cases highlight the utility of daratumumab with cyclophosphamide, bortezomib, and dexamethasone for acute renal failure in newly-diagnosed multiple myeloma and a clinical diagnosis of cast nephropathy.
SiegelRLMillerKDWagleNS, et alCancer statistics, 2023. CA Cancer J Clin2023; 73(1): 17–48.
2.
KnudsenLMHjorthMHippeE, et alRenal failure in multiple myeloma: reversibility and impact on the prognosis. Eur J Haematol2000; 65(3): 175–181.
3.
RajkumarSVDimopoulosMAPalumboA, et alInternational Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol2014; 15(12): e538–e548.
4.
HerreraGASandersPW.Paraproteinemic renal diseases that involve the tubulo-interstitium. Contrib Nephrol2007; 153: 105–115.
UttervallKDuruADLundJ, et alThe use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment. PLoS One2014; 9(7): e101819.
7.
SwanDHendersonRMcEllistrimC, et alCyBorD-DARA in newly diagnosed transplant-eligible multiple myeloma: results from the 16-BCNI-001/CTRIAL-IE 16-02 study show high rates of MRD negativity at end of treatment. Clin Lymphoma Myeloma Leuk2022; 22(11): 847–852.
8.
FaconTKumarSKPlesnerT, et alDaratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol2021; 22(11): 1582–1596.
9.
JakubowiakAJKumarSMedhekarR, et alDaratumumab improves depth of response and progression-free survival in transplant-ineligible, high-risk, newly diagnosed multiple myeloma. Oncologist2022; 27(7): e589–e596.
10.
TheprungsirikulPLiuYNeparidzeN.Real-world utilization of daratumumab in front-line treatment of newly diagnosed multiple myeloma: a retrospective observational study. Blood2023; 142(Supplement 1): 7364.
11.
JeyaramanPBhasinADayalN, et alDaratumumab in dialysis-dependent multiple myeloma. Blood Res2020; 55(1): 65–67.
12.
RocchiSTacchettiPPantaniL, et alSafety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma. Haematologica2018; 103(6): e277–e278.
13.
SmythEGlaveySMelottiD, et alDialysis independence following single-agent daratumumab in refractory myeloma with renal failure. Ir J Med Sci2019; 188(3): 1079–1080.
